Since the end of the eighty-year-long prohibition on industrial hemp, there has been a surge in market demand for hemp-derived products. The range of these products varies from topicals and tinctures to textiles and even construction-grade concrete (also known as ‘Hempcrete’). As a result, farmers have been racing to grow enough industrial hemp to meet the ever-growing demand. The introduction of the 2018 Farm Bill enabled hemp farmers to obtain that crop insurance and released farmers from many restrictions at the federal level. These advances led farmers across the country to join this potentially lucrative supply chain. This article will walk you through the origin of the Matterhorn CBG Varietal, as well as the medical potential and the market potential that comes from farming this very revolutionary cannabinoid.
Medical Potential of CBG
Hemp-derived cannabinoids have made an impact in both the medical field and in consumer goods. The cannabinoid that is most commonly known is CBD, but there is no reason not to believe that CBG products won’t follow this billion dollar trend. CBG is a minor cannabinoid that is making major waves in the industry.
CBG (also known as Cannabigerol) stands out from the crowd of hemp-derived cannabinoids for one fascinating reason. It is known as the “Mother” or “OG” cannabinoids due to the fact that it is the precursor to all other cannabinoids such as CBD (Cannabidiol), CBN (Cannabinol) CBC (Cannabichromene) and THCA (Tetrahydrocannabinolic Acid).
Besides being the Mother of the other cannabinoids, CBG activates both CB1 and CB2 receptors in the Endocannabinoid System. This means that it could potentially hold the cumulative qualities of all the other cannabinoids put together.
Understanding the Potential Health Benefits of CBG
Understanding the endocannabinoid system makes it easy to see why CBG is such a game changer. Here are the basics:
- The human body’s central nervous system is made up of nerve cells that release chemicals called neurotransmitters.
- Neurotransmitters carry messages that regulate performance and activity of various body parts and systems.
- Neurotransmitters are released and then in turn taken up, or reabsorbed, by the receiving cell terminal or receptor.
- Nerve cells also secrete endocannabinoids, which are cannabinoids created by the human body, to regulate cellular function and maintain homeostasis.
- The system of nerves cells that regulate cannabinoid secretion and reuptake is called the Endocannabinoid system, ECS.
- When this system gets out of balance, plant-derived cannabinoids, or phytocannabinoids such as CBG and CBD, can be introduced to balance and alleviate various physical ailments.
The coming years of research will enlighten us all to the myriad uses of CBG and its ability to balance the ESC. Here are a few of the areas researchers are currently looking at in regard to the medicinal value of CBG.
- Stomach and Bone Cancer
- Prostate, breast, and bladder cancer
- Colorectal cancers
- Pain Relief
- Inflammatory Bowel Disease
- Neuroprotective Agent
- Oral Bacteria
- Parkinson’s Disease
- Huntington’s Disease
- Motor Disorders
The CBG Market Potential
While the research is still in the early stages, scientists the world over have transitioned resources and focus on this powerful molecule and the downstream market is taking notice. Industrial hemp markets are poised to continue their upward growth. Projections are that the industrial hemp market will grow from 4.6 billion in 2019 to 26.6 billion by 2025.
According to Sean Williams of the Motley Fool the global cannabis market, which includes sales estimates for 22 counties, should grow from $17 billion in 2019 to $50 billion by 2029.
When viewed from the perspective of medical advances, and pharmaceutical breakthroughs, and consumer goods CBG hemp varietials are well-positioned to be in the forefront of this growing sector.
Is CBG Ready for the Big Leagues?
CBG is poised to make a substantial impact in the medical and consumer goods pharmaceutical markets. In the past there was one factor limiting CBGs introduction into these markets on a large scale. This factor was the relatively low levels of CBG found in each plant.
Following the laws of supply and demand meant that the production costs were high, prohibitively so. Because of the normally low levels of CBG in an industrial hemp plant, and it’s high potency for medical applications, CBG has been nicknamed the “Rolls Royce” of cannabinoids.
Previously available varietals of CBG contained low quantities of CBG making growing hemp for focused CBG production cost-prohibitive. According to Janelle Lassalle of Forbes magazine, “Either you give up your entire crop to process and produce pure CBG prior to the conversion into other cannabinoids, or you wait until it’s time to harvest the hemp plant”, says Floyd Landis, founder of the retail outlet Floyd’s of Leadville.”
The solution to this problem is pinpointed in a recent Forbes article, to summarize: the genetics of the plant is still the primary price factor. It follows that if you breed higher CBG hemp strains, the cost to extract the CBG goes way down because you need much less material to extract it. This problem has been solved and CBG is ready to join the big leagues of the green rush.
The Story of Matterhorn CBG Hemp Seed Genetics
One Italian geneticist has dedicated the last several years to unlocking the hemp seed genetics that would open up CBG production and its introduction into the wide market. This strain will make CBG a viable force in the hemp industry.
The story of Matterhorn CBG is a story of faith and perseverance. It begins in 2016, with an Italian breeder named Matthais Ghidossi who was working in Switzerland and in partnership with a company operating in medical THC production for the Swiss government. At that stage, the Swiss market was already showing some really promising results in terms of CBG genetics, but our breeder was searching for new material to work with by way of using real industrial hemp strains.
He decided to purchase some Carmagnola seeds. Carmagnola is a varietal that has been grown in Italy for more than 15 years and has a reputation of being consistently well within THC compliance levels. Matthias planted about 6000 of these seeds in Switzerland and started selecting anything that had an interesting terpene profile or flower structure.
Then it happened: the dream came to fruition. In a poeticized rendition, his eye was caught by a glint of white across a sun-drenched field of hemp. This particular plant had an intense white flower that made it stand out – even at a distance.
Upon closer inspection, this flower had a very different terpene profile than usual Carmagnola. It was this plant, with its white flower, that became the original mother of Matterhorn. She contained about 5% CBG, which was causing the white color in the bud.
Matthias was obviously enthusiastic and started to believe he had discovered something very special. After 3 years and a lot of diligent work, Matterhorn CBG (known as Perugina in the EU) has finally made a name for itself in the marketplace.
The breakthrough that makes Matterhorn CBG stand out in its class is its consistently high levels of CBG, consistently testing at 12.46% and up to 15% CBG. These high levels are reached while maintaining compliance with THC regulations. Matterhorns THC levels test at 0.09%. These game changing results are the reason why Matterhorn derived its name from the tallest mountain in the Swiss Alps.
Farming for CBG is Now Possible with Matterhorn
Matterhorn CBG has two years of field trials and has proven itself to be uniform, stable, and unique. Germination rates are at 95% and feminization rates are 98%, producing one male to every 4000 females. The high level of CBG and THC compliance make it a good option for farmers looking to get into the CBG market or to diversify.
Besides being an ideal candidate for CBG extraction, Matterhorn is also highly smokable. The breeder paid close attention to the terpene profile which is described as having effervescent notes of citrus with notes of lemon and lime.
Matterhorn CBG is the perfect example of why it’s important for farmers to use original genetics. Quality, compliance, and consistency vary from breeder to breeder, and that’s what makes this CBG varietal stand out from the rest.
The green rush following the signing of the 2018 Farm Bill has led farmers across the country to transition their operations to include fields or greenhouses of industrial hemp. While CBD has taken much of the seed genetic spotlight, the medical and market potentials are now illuminating CBG.
CBG has the potential to revolutionize the pharmaceutical and consumer goods markets of hemp-derived products. Big players are getting into the cannabinoid market and there is unlimited potential. Matterhorn CBG, with its high levels of CBG, can be the strain that breaks down the barriers of both the pharmaceutical and consumer goods markets.
High Grade Offers Matterhorn CBG
We are unequivocally enthusiastic about Matterhorn CBG. Matterhorn is now available in the United States, and we encourage farmers to grow Matterhorn CBG for its enormous potential, compliance, and stability. Farmers know that good harvests come from good seed genetics and that is what you get from High Grade.
Our collection also includes Berry Blossom, Cherry Wine, Merlot, Red Bordeaux, and Bueno. We offer Early Finishers, Auto Flower and Full-Term cultivars. This selection allows farmers the flexibility they need to maximize greenhouse space, acreage, and labor.